发明授权
US07723333B2 Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators
失效
异噻唑-3（2H） - 酮1,1-二氧化物的非苯胺衍生物作为肝X受体调节剂
- 专利标题： Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators
- 专利标题（中）： 异噻唑-3（2H） - 酮1,1-二氧化物的非苯胺衍生物作为肝X受体调节剂
-
申请号： US11813470申请日： 2006-01-09
-
公开(公告)号： US07723333B2公开(公告)日： 2010-05-25
- 发明人: Anders Broo , Robert Judkins , Lanna Li , Eva-Lotte Lindstedt-Alstermark , Pernilla Sandberg , Marianne Swanson , Lars Weidolf , Kay Brickmann , Patrik Holm
- 申请人： Anders Broo , Robert Judkins , Lanna Li , Eva-Lotte Lindstedt-Alstermark , Pernilla Sandberg , Marianne Swanson , Lars Weidolf , Kay Brickmann , Patrik Holm
- 申请人地址： SE Sodertalje
- 专利权人： AstraZeneca AB
- 当前专利权人： AstraZeneca AB
- 当前专利权人地址： SE Sodertalje
- 代理机构： Pepper Hamilton LLP
- 优先权： SE0500055 20050110
- 国际申请： PCT/SE2006/000029 WO 20060109
- 国际公布： WO2006/073366 WO 20060713
- 主分类号： A61K31/5355
- IPC分类号： A61K31/5355 ; A61K31/501 ; A61K31/4523 ; A61K31/4427 ; A61K31/427 ; A61K31/4155 ; C07D275/02 ; C07D233/54 ; C07D413/02 ; C07D401/02 ; C07D239/02 ; C07D211/00 ; C07D417/02
摘要：
The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.
公开/授权文献
信息查询
